The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.
December 19th 2024
Study findings suggest the potential utility of ΔADC for assisting the clinical, pathological, and prognostic risk stratification of patients with IgAN.
Clinical, Pathological Distinctions Provide Basis for Differentiating IgAN, IgAVN
February 7th 2024Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.
Hydroxychloroquine, Leflunomide Improve Proteinuria, Renal Function in IgAN
February 5th 2024Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.
72-Week Phase 2B ORIGIN Data Highlight Potential Benefit of Atacicept in IgA Nephropathy
January 25th 2024The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators
Patients with IgA Nephropathy May Not Be Receiving Optimal Supportive Care
January 24th 2024Results called attention to suboptimal blood pressure and proteinuria control as well as a lack of maximal RAASI dosing in a cohort of adult patients with IgAN from the Cure Glomerulonephropathy Network study.
Corticosteroids Induce Remission in Patients With IgA Nephropathy, Moderate Proteinuria
January 19th 2024Patients with IgAN and urine protein levels of 0.75–3.5 g/d treated with corticosteroids exhibited significantly greater overall and complete remission rates compared to those who received supportive care.
Clinical, Prognostic Factors Affecting Concurrent IgAN and Membranous Nephropathy Outcomes
January 15th 2024Results of the retrospective study suggested blood pressure, serum IgA, potassium, and segmental glomerulosclerosis may be predictive of the rapid progression of renal endpoints in patients with concurrent IgAN and membranous nephropathy.
Risk Factors for IgA Nephropathy Recurrence After Kidney Transplant
January 10th 2024Younger age at the time of kidney transplantation, faster progression to end-stage renal disease, a history of kidney transplantation, and no induction therapy were associated with IgAN recurrence, which was linked to poorer graft survival.
Gross Hematuria Observed in Patients with IgA Nephropathy After COVID-19 Vaccination
November 16th 2023In the new study, 71% of the patients who developed gross hematuria after a COVID-19 vaccination were females, and for 92% of the patients, the investigators observed gross hematuria had developed after the second or subsequent vaccinations.